A peptide inhibitor of Cx43 hemichannels
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tat-Gap 19 (trifluoroacetate salt)

Item No. 36729

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-tyrosylglycyl-L-arginyl-L-lysyl-L-lysyl-L-arginyl-L-arginyl-L-glutaminyl-L-arginyl-L-arginyl-L-arginyl-L-lysyl-L-glutaminyl-L-isoleucyl-L-α-glutamyl-L-isoleucyl-L-lysyl-L-lysyl-L-phenylalanyl-L-lysine, trifluoroacetate salt
Molecular Formula
C119H212N46O26 • XCF3COOH
Formula Weight
2703.3
Purity
≥95%
Formulation (Request formulation change)
A solid
Peptide Sequence
YGRKKRRQRRRKQIEIKKFK-OH
Solubility(Learn about Variance in Solubility)
Water: Soluble
SMILES
OC(C(F)(F)F)=O.O=C(NCC(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN[H])C(N[C@@H](CCCCN[H])C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN[H])C(N[C@@H](CCC(N)=O)C(N[C@@](C(N[C@@H](CCC(O)=O)C(N[C@@](C(N[C@@H](CCCCN[H])C(N[C@@H](CCCCN[H])C(N[C@H](C(N[C@@H](CCCCN[H])C(O)=O)=O)CC1=CC=CC=C1)=O)=O)=O)([H])[C@@H](C)CC)=O)=O)([H])[C@@H](C)CC)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC2=CC=C(O)C=C2)N[H]
InChi Code
InChI=1S/C119H212N46O26.C2HF3O2/c1-5-67(3)93(111(188)160-78(34-14-20-56-124)100(177)152-77(33-13-19-55-123)106(183)163-88(65-69-28-8-7-9-29-69)110(187)162-87(113(190)191)35-15-21-57-125)165-109(186)86(48-51-92(170)171)161-112(189)94(68(4)6-2)164-108(185)85(47-50-90(128)168)159-99(176)76(32-12-18-54-122)151-101(178)79(37-23-59-142-115(131)132)154-103(180)81(39-25-61-144-117(135)136)155-104(181)82(40-26-62-145-118(137)138)157-107(184)84(46-49-89(127)167)158-105(182)83(41-27-63-146-119(139)140)156-102(179)80(38-24-60-143-116(133)134)153-98(175)75(31-11-17-53-121)150-97(174)74(30-10-16-52-120)149-96(173)73(36-22-58-141-114(129)130)148-91(169)66-147-95(172)72(126)64-70-42-44-71(166)45-43-70;3-2(4,5)1(6)7/h7-9,28-29,42-45,67-68,72-88,93-94,166H,5-6,10-27,30-41,46-66,120-126H2,1-4H3,(H2,127,167)(H2,128,168)(H,147,172)(H,148,169)(H,149,173)(H,150,174)(H,151,178)(H,152,177)(H,153,175)(H,154,180)(H,155,181)(H,156,179)(H,157,184)(H,158,182)(H,159,176)(H,160,188)(H,161,189)(H,162,187)(H,163,183)(H,164,185)(H,165,186)(H,170,171)(H,190,191)(H4,129,130,141)(H4,131,132,142)(H4,133,134,143)(H4,135,136,144)(H4,137,138,145)(H4,139,140,146);(H,6,7)/t67-,68-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,93-,94-;/m0./s1
InChi Key
OUQZHHJZEOMXDH-UTLSFRJRSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 µg

    $127

    Add

    1 mg

    $241

    Add

    5 mg

    $633

    Add
    Product Description

    Tat-Gap 19 is a peptide inhibitor of connexin43 (Cx43) hemichannels.1 It is composed of the HIV-1 Tat protein transduction domain linked to a nine-amino acid peptide corresponding to residues 128-136 of Cx43. Tat-Gap 19 (10 µM) inhibits glutamate-induced ATP release, a marker of Cx43 hemichannel activity, in primary rat hepatocytes.2 It reduces infarct volume in a mouse model of cerebral ischemia-reperfusion injury induced by middle cerebral artery occlusion (MCAO) when administered at a dose of 25 mg/kg.1 Intraperitoneal infusion of Tat-Gap 19 (1 mg/kg per day) reduces fibrotic lesion area and the area of hepatic stellate cells, precursors of myofibroblasts, expressing α-smooth muscle actin (α-SMA) in a mouse model of thioacetamide-induced liver injury.2 It increases superoxide dismutase (SOD) activity in hepatic cells isolated from the same mice.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Chen, B., Yang, L., Chen, J., et al. Inhibition of Connexin43 hemichannels with Gap19 protects cerebral ischemia/reperfusion injury via the JAK2/STAT3 pathway in mice. Brain Res. Bull. 146, 124-135 (2019).

    2. Crespo Yanguas, S., da Silva, T.C., Pereira, I.V.A., et al. TAT-Gap19 and carbenoxolone alleviate liver fibrosis in mice. Int. J. Mol. Sci. 19(3), 817 (2018).